氯化锶和^(99)Tc-亚甲基二膦酸盐治疗泌尿系肿瘤骨转移癌的临床观察

Clinical observation of ^(89)SrCl_2 and ^(99)Tc-MDP in the treatment of bone metastatic cancer of urinary tumors

目的 :评价氯化锶 (89SrCl2 )、99Tc 亚甲基二膦酸盐 (99Tc MDP)以及联合应用于泌尿系肿瘤骨转移癌的疗效。方法 :以 33例泌尿系恶性肿瘤并多发性骨转移患者为观察对象 ,其中89SrCl2 治疗组 16例、99Tc MDP治疗组 9例、89SrCl2 和99Tc MDP联合治疗组 8例 ,所有病例均随访观察 3个月。结果 :89SrCl2 治疗组和99Tc MDP治疗组镇痛总有效率分别为 81.3%和 6 6 .7% ,对骨病变有效率分别为 31.2 %和 2 2 .2 % ,两组上述两个指标比较差异均无显著性意义 (P >0 .0 5 )。而联合应用89SrCl2 和99Tc MDP治疗组镇痛总有效率为 87.5 % ,与前两组相比差异无显著性意义 (P >0 .0 5 ) ;对骨病变有效率为 6 2 .5 % ,与前两组比较差异有显著性意义 (P <0 .0 5 )。三组病例毒副作用均较小。结论 :89SrCl2 和99Tc MDP均对骨转移癌的疼痛有较好疗效 ,联合应用可能会进一步提高疗效 。

Purpose:To study the effect of 89SrCl 2 and 99Tc-MDP, which were used either separately or jointly, in the treatment of bone metastatic cancer of urinary tumors.Method: 33 cases of urinary malignant tumors complicated with bone metastatic cancer were enlisted in this study, which were divided into 3 groups to be respectively treated with single 89SrCl 2 (n=16), single 99Tc-MDP ( n=9) or combined use of these 2 agents (n=8), and were all conducted with a 3-month follow up after the treatment.Result: In view of the total pain-relief rates of the bone, 89SrCl 2, 99Tc-MDP and their combined use did not make significant difference ( 81.3%, 66.7% and 87.5% respectively, P> 0.05). As for the rates of the bone lesion improvement, the combined medication yielded a rate as much as 62.5%,significantly better than that of their separate uses( 31.2%, 22.2% respectively, P< 0.05). The toxic and side effects were negligible in all cases of 3 groups.Conclusion: In treating bone metastatic cancer of urinary tumors, 89SrCl 2 and 99Tc-MDP have effect, and it will be more desirably effective to use them jointly.